Targeted drug aims to stop blood cancer return after transplant
NCT ID NCT05233618
First seen Jul 16, 2026 · Last updated Jul 17, 2026 · Updated 1 time
Summary
This phase 1 trial tests whether the drug tagraxofusp can help prevent relapse in people with certain blood cancers (acute myeloid leukemia, myelodysplastic syndrome, myelofibrosis, or chronic myelomonocytic leukemia) who have recently received a stem cell transplant. Participants receive up to about 9 cycles of tagraxofusp, which targets cancer cells that carry a protein called CD123. The study focuses on safety and how much of the drug patients can tolerate.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- tagraxofusp (also known as Elzonris), a drug that targets CD123-positive cells
- What this could lead to
- If successful, this approach could help prevent relapse after stem cell transplant for certain blood cancers, potentially improving long-term survival.
- What could go wrong
- This is an early phase 1 trial with a small number of participants, so safety and effectiveness are not yet proven. Side effects, including serious ones, are possible.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE MYELOID LEUKEMIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Thomas Jefferson University
Philadelphia, Pennsylvania, 19107, United States
-
University of Virginia
Charlottesville, Virginia, 22901, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a gentler chemo-radiation combo make stem cell transplants safer for blood cancers?
- Can a targeted drug plus donor immune cells fight back against relapsed leukemia?
- Can a Two-Drug combo outsmart a deadly leukemia?
- Can a new pill take on Hard-to-Treat leukemia?
- Can pressurized oxygen boost cord blood transplants?
- Leukemia drug cocktail aims to boost remission in High-Risk patients